CN107348522A - A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof - Google Patents

A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof Download PDF

Info

Publication number
CN107348522A
CN107348522A CN201710693890.2A CN201710693890A CN107348522A CN 107348522 A CN107348522 A CN 107348522A CN 201710693890 A CN201710693890 A CN 201710693890A CN 107348522 A CN107348522 A CN 107348522A
Authority
CN
China
Prior art keywords
vitamin
parts
elderly
improving
whey protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710693890.2A
Other languages
Chinese (zh)
Inventor
陈朝青
何梅
王学敏
张燕
伍敏晖
韩丽丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Nutrient Source Research Institute
Original Assignee
Beijing Nutrient Source Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Nutrient Source Research Institute filed Critical Beijing Nutrient Source Research Institute
Priority to CN201710693890.2A priority Critical patent/CN107348522A/en
Publication of CN107348522A publication Critical patent/CN107348522A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a kind of alimentation composition for improving the elderly's kinematic system function and preparation method and application, and the alimentation composition is made up of following composition by weight：10 15 parts of lactalbumin, 0.5 1 parts of whey protein peptide, 0.5 1 parts of wheat protein peptide, 2 10 parts of collagen peptide, 0.05 0.15 parts of CPP, 25 parts of leucine, 0.5 3 parts of β hydroxyl β methylbutanoic acids, 0.5 1 parts of calcium, 0.2 0.5 parts of magnesium, 5 20 parts of chick sternal cartilage, 0.1 0.5 parts of chitosan oligosaccharide, 0.5 2 parts of dimethyl sulfone, 0.1 1 parts of curcumin, 0.02 0.15 parts of vitamin mixtures.The present invention realizes required nutritional ingredient based on the theoretical thought of system trophism, specific aim supplement the elderly's kinematic system functional status.Promote to realize the holistic health of the elderly's kinematic system by the function collaboration of each nutrient.

Description

Nutritional composition for improving motor system function of old people and preparation method thereof
Technical Field
The invention relates to a nutritional composition for improving the motor system function of the elderly, and a preparation method and application thereof.
Background
The global aging speed is increasing. The predictions promulgated by the united nations show that the world's proportion of the elderly population over 60 years of age is about 10.0% in 2000, will rise to 15.1% in 2025, and will be as high as 21.7% in 2050. With the aging, the physiological functions of the locomotor system of the human body are gradually degraded, most of the elderly have the problems of osteoporosis, degenerative osteoarthropathy (articular cartilage degradation) and skeletal muscle reduction, the consequences of which often cause the activity of the elderly to be reduced, and daily actions such as walking, sitting, ascending, lifting heavy objects and the like to be affected, even cause balance disorder, difficulty in standing, great easiness in falling and the like.
The locomotor system consists of three organs, bone joints (joints) and skeletal muscle. Bones are joined together in different joints (inactive, semi-active, or active) to make up the skeleton. Forms the basic shape of the human body and provides attachment for muscles which contract under the nerve innervation, pulling the attached bone, pivoting on the movable bone connection, creating a lever motion. From the kinematic perspective, the bone is the passive part, the skeletal muscle is the dynamic part, and the joint is the kinematic hinge. In fact, the three muscles, bones and bone joints are closely related in the movement function and have mutual regulation.
According to the consensus of the experts of muscle, bone and osteoporosis, osteoporosis is closely related to muscle and bone. Osteoporosis and sarcopenia present many common risk factors. The motor systems of muscles and bones are all originated from mesoderm and have common mesenchymal precursors, and the two are closely related in motor functions. Muscle is a ligament that connects bones and is closely related to the growth and development of bones. Recent researches find that muscles and bones are important endocrine organs, relevant factors secreted by the muscles are involved in regulation and control of the bones and have certain influence on growth, development and development of the bones, and the bone factors can also regulate muscle mass and muscle strength. Developmental biology studies suggest that there may be molecular signaling networks that coordinate muscle and bone mass, and regulatory factors that can couple muscle and skeletal growth in the circulation and local microenvironment. Muscles and bones are also regulated by each other, in addition to being influenced by both internal (neuroendocrine) and external (force) factors.
The development, function and aging of the skeletal muscle system are an organic whole. The strength of muscle contraction under the control of the nervous system is an important factor determining the bone mass and strength. The effect of muscle strength on bone density is more pronounced than the effect of muscle content on bone density. The number of skeletal muscles is an important factor in determining bone density. The number of muscles and the bone density are increased and decreased synchronously. Loss of skeletal muscle can lead to decreased bone density. Muscular atrophy, muscle strength decline and muscle function decline can lead to accelerated and thinned cortical bone absorption and weakened ability to resist shear force, torsion and bending force; the number of horizontal trabeculae in the cancellous bone is reduced, the vertical trabeculae become sparse, and the bone density becomes lower and lower. The bone adapts to the changes in the strength of muscle contraction by changing the bone mass and strength. The mechanical stimuli to which bones are subjected have a significant effect on bone density. Bone cells convert mechanical stimuli into biochemical signals that regulate bone density. The decrease in bone density is a result of an imbalance in the regulation of the musculoskeletal system.
Degenerative osteoarthropathy, also known as osteoarthritis, is a degenerative disease, which is degenerative injury of articular cartilage, reactive hyperplasia of articular margin and subchondral bone caused by aging, obesity, strain, trauma, congenital abnormality of joints, joint deformity, etc. Studies have shown that cartilage is nutritionally impaired, cartilage matrix is degraded over synthesis, and reduced repair capacity is a major cause of degenerative joint disease. The research result of the knee arthritis shows that the weakness of the skeletal muscle of the knee joint (skeletal muscle atrophy and muscle strength decline) is an important pathological link of the knee arthritis, and is generally considered to be caused by muscle inhibition and secondary atrophy caused by arthritis pain. And it has been considered that age-related quadriceps femoris weakness plays an important role in the pathogenesis of knee osteoarthritis.
However, in the fields of nutrition and food, the intervention on the motion system is mostly part of individual intervention, and no systemic overall consideration exists. Such as calcium and/or vitamin D to improve osteoporosis, glucosamine to relieve joint cartilage degradation. And loss of skeletal muscle is largely ignored by the general public.
Generally, most old people have the problems of osteoporosis, degenerative osteoarthropathy (articular cartilage degeneration) and skeletal muscle reduction, and the vitamin D calcium tablets for improving osteoporosis and the glucosamine for relieving joint degeneration cannot integrally improve the motion system, so that the effect is single and the product is not an ideal product.
Disclosure of Invention
The invention aims to provide a nutritional composition for improving the motor system function of the elderly, a preparation method and application thereof, and the nutritional composition can improve the motor system function of the elderly from three aspects of muscles, bones and bone joints.
In order to achieve the purpose, the invention adopts the following technical scheme:
a nutritional composition for improving the motor system function of the elderly comprises the following components in parts by weight: 10-15 parts of whey protein, 0.5-1 part of whey protein peptide, 0.5-1 part of wheat protein peptide, 2-10 parts of collagen peptide, 0.05-0.15 part of casein phosphopeptide, 2-5 parts of leucine, 0.5-3 parts of beta-hydroxy-beta-methylbutyric acid, 0.5-1 part of calcium, 0.2-0.5 part of magnesium, 5-20 parts of chicken breast cartilage powder, 0.1-0.5 part of chitosan oligosaccharide, 0.5-2 parts of dimethyl sulfone, 0.1-1 part of curcumin and 0.8-1.2 parts of vitamin mixture.
Preferably, the nutritional composition for improving the motor system function of the elderly consists of the following components in parts by weight: 12-15 parts of whey protein, 0.5-0.8 part of whey protein peptide, 0.5-0.8 part of wheat protein peptide, 3-10 parts of collagen peptide, 0.05-0.1 part of casein phosphopeptide, 2-4 parts of leucine, 1-3 parts of beta-hydroxy-beta-methylbutyric acid, 0.5-0.8 part of calcium, 0.2-0.4 part of magnesium, 10-20 parts of chicken breast cartilage powder, 0.2-0.5 part of chitosan oligosaccharide, 1-2 parts of dimethyl sulfone, 0.5-1 part of curcumin and 0.9-1.1 part of vitamin mixture.
Further preferably, the nutritional composition for improving the motor system function of the elderly consists of the following components in parts by weight: 14-15 parts of whey protein, 0.6-0.7 part of whey protein peptide, 0.6-0.7 part of wheat protein peptide, 5-10 parts of collagen peptide, 0.05-0.8 part of casein phosphopeptide, 3-4 parts of leucine, 2-3 parts of beta-hydroxy-beta-methylbutyric acid, 0.5-0.6 part of calcium, 0.2-0.3 part of magnesium, 15-20 parts of chicken breast cartilage powder, 0.3-0.5 part of chitosan oligosaccharide, 1.5-2 parts of dimethyl sulfone, 0.5-0.8 part of curcumin and 0.9-1.0 part of vitamin mixture.
Further, the vitamin mixture contains vitamin B group, vitamin D, vitamin C, vitamin E, and vitamin K2(ii) a Also contains proper amount of carrier which can be used in the field.
Further, each vitamin in said vitamin mixture is present in an amount of 1gThe contents are as follows: vitamin B group 12-42mg, vitamin D3-10 μ g, vitamin C30-100 mg, vitamin E5-15 mg, vitamin K270-90μg。
Still further, the content of each vitamin in each 1g of the vitamin mixture is: vitamin B20-42 mg, vitamin D5-10 μ g, vitamin C50-100mg, vitamin E10-15 mg, and vitamin K280-90μg。
Preferably, the content of each vitamin in each 1g of the vitamin mixture is: vitamin B42 mg, vitamin D8 μ g, vitamin C100mg, vitamin E14mg, vitamin K290μg。
The calcium can be provided by calcium-containing mineral substances such as calcium hydrophosphate, calcium carbonate and the like; the magnesium may be provided by magnesium sulfate magnesium-containing minerals.
The raw materials of the invention are all available on the market.
The invention also provides a preparation method of the nutritional composition for improving the motor system function of the old, which can be prepared by taking the raw materials according to the proportion by a conventional method in the field and uniformly mixing the raw materials. Generally, the raw materials can be uniformly mixed by adopting an equivalent incremental method and using a three-dimensional V-shaped mixer for mixing for about 5-10 min.
The recommended dose of the nutritional composition for improving the motor system function of the elderly is 35-50 g/day.
The significant improvement can be achieved by taking the medicine continuously for 30 to 60 days.
The invention also provides a preparation containing the nutritional composition for improving the motor system function of the old.
Furthermore, the preparation also contains auxiliary materials and/or additives used in the fields of food and health-care food; alternatively, the formulation further comprises a pharmaceutically acceptable carrier.
The preparation can be prepared by adding adjuvants, additives, carriers, etc. commonly used in food field, health food field or pharmacy, such as carrier, excipient, diluent, disintegrating agent, aromatic, colorant, sweetener, such as microcrystalline cellulose used as excipient and/or disintegrating agent.
The formulation may be in various conventional forms in the art, such as tablets (including chewable tablets), capsules, granules, tabletted candies, powders, and the like. For example, the nutritional composition for improving the motor system function of the elderly can be directly filled into capsules to prepare capsules; or granulating, drying, and making into tablet.
The nutritional composition and the preparation thereof for improving the motor system function of the elderly can be directly used as terminal food and also can be used as ingredients of food or health-care food.
The invention also comprises the application of the nutritional composition or the preparation thereof for improving the motor system function of the elderly in preparing food, health-care products or medicines.
Compared with the prior art, the invention has the following beneficial effects:
in terms of improving muscle attenuation:
(1) through the combination of whole protein (whey protein) and hydrolyzed protein (whey protein peptide and collagen peptide), gradient absorption of protein is formed, and energy and raw materials are continuously provided for muscles;
(2) the whey protein contains high leucine, and meanwhile, part of leucine and a metabolite beta-hydroxy-beta-methylbutyric acid thereof are supplemented, the leucine promotes the strongest synthesis of skeletal muscle protein, the beta-hydroxy-beta-methylbutyric acid is beneficial to promoting the increase of muscle volume to the maximum extent, and the muscle mass and function reduction of the old can be reversed by cooperating with other nutrient substances;
(3) the vitamin B group participates in energy metabolism, and can further regulate muscle energy supply. The supply of energy is an important source of muscle strength. The vitamins participating in energy metabolism with coenzyme or prosthetic group are mainly B vitamins, and mainly comprise VB1, VB2 and VB 6. The active form of VB1 constitutes the coenzyme of the α -keto acid dehydrogenase system and transketolase in vivo and is mainly involved in the metabolism of sugars and branched-chain amino acids. VB2 is bound to specific proteins in vivo in the form of flavin mononucleotide and flavin adenine dinucleotide coenzyme, and is widely involved in redox reactions in metabolism. Since flavin adenine dinucleotide is a component of the respiratory chain, VB2 is a central link for energy production. VB6 in its active form pyridoxal 5' -phosphate is involved in amino acid metabolism as a coenzyme for many enzymes (e.g., transaminases, decarboxylases).
(4) Vitamin D is added to increase muscle strength and function. Vitamin D functions via the following two pathways: in one aspect, vitamin D promotes muscle fiber synthesis by binding to specific vitamin D receptors on the surface of skeletal muscle cells, resulting in increased mRNA expression. On the other hand, vitamin D can increase calcium storage of sarcoplasmic reticulum and promote muscle contraction function.
(5) The wheat protein peptide contains rich glutamine, the glutamine is the amino acid which is most consumed by metabolism under the stress state of a human body and is also the amino acid with the most content in the skeletal muscle of the human body, the volume of muscle cells can be increased, the decomposition of protein is inhibited, and meanwhile, the glutamine can regulate the intestinal barrier function and the immunity of the old and promote the absorption of nutrient components;
(6) the oxidative stress of muscle is reduced by supplementing vitamin C and vitamin E with antioxidant effect. Reduce the damage to the muscle caused by oxidative stress and maintain the muscle function.
In the aspect of improving osteoporosis:
(1) supplement the main components of bone, calcium and collagen (peptides). 97-98% of bone tissue is bone matrix, 65% of vitamin mineral substance in the bone matrix, 35% of organic substance in the bone matrix, and 95% of the organic substance is collagen. Calcium and collagen supplementation can help to increase the strength and toughness of bones, thereby improving osteoporosis;
(2) supplementing vitamin K2. Vitamin K2 plays an important role in various links of bone metabolism, has two-way effects of promoting bone formation and inhibiting bone resorption, and can improve the unbalanced state of bone tissue metabolism and bone quality, thereby increasing bone strength.
(3) Supplementing casein phosphopeptide and vitamin D. The casein phosphopeptide can promote the absorption of calcium by small intestine. Vitamin D can promote absorption of calcium and phosphorus by intestinal tract, and can stimulate osteoblast to promote maturation of bone-like tissue and bone salt deposition.
(4) Supplementing vitamin C, and promoting bone collagen regeneration. In the synthesis of collagen, proline and lysine residues in the polypeptide chain must be hydroxylated into hydroxyproline and hydroxylysine residues under the catalysis of proline carboxylase and lysine hydroxylase. Vitamin C is one of the accessory factors necessary for the maintenance of the activity of these hydroxylases.
(5) And supplementing magnesium. Magnesium is an element essential for bone cell structure and function, which allows bone growth and maintenance, and it can affect bone resorption.
In the aspect of improving the articular cartilage damage:
(1) the chicken breast cartilage powder contains rich collagen, glucosamine, chondroitin sulfate and other important bone joint components, contains various active factors such as basic fibroblast growth factor, insulin-like growth factor and the like, and can promote the growth of chondrocytes, accelerate the synthesis of bone matrix so as to promote the repair of articular cartilage and slow down the degradation of articular cartilage;
(2) dimethyl sulfone is one of the major supplies of sulfur in the human body for the synthesis of methionine, cystine and sulfur-containing peptides, proteins, and sulfur-containing tissues. The mucous membrane at the joint consists of sulfur-containing protein, glucosamine and the like. The sulfur-containing protein and glucosamine have the functions of promoting the production of collagen, increasing the combination of water and helping to repair damaged cartilage. Can restore the injured cartilage to be normal, and the periosteal fluid is more concentrated and viscous, thereby strengthening the protective function of periosteum, relieving the friction of bone joints and reducing the pain.
(3) The chitosan oligosaccharide is an oligosaccharide formed by connecting 2-10 glucoseamine through beta-1, 4 glycosidic bonds, can promote the repair of synovium and cartilage, reduce inflammatory transmitters in joint synovial fluid, and effectively improve the symptoms of osteoarthritis.
(4) Curcumin and turmeric are also traditional blood-activating and stasis-removing medicines, and can activate blood, promote qi circulation and relieve pain. The effect of protecting articular cartilage against osteoarthritis is mainly achieved by: curcumin can remove free radicals by inhibiting oxidase, and has antioxidant effect, thereby preventing osteoarthritis; curcumin inhibits the consumption of matrix metalloproteinase to cartilage matrix and increases the generation of type II collagen; curcumin accomplishes anti-inflammatory response by inhibiting cytosolic phospholipase a2, cyclooxygenase 2, lipoxygenase 5.
The invention is based on the thought of the system nutrition theory, and is integrally considered from three aspects of bones, joints and muscles, thereby pertinently supplementing the functional state of the motion system of the old people with the required nutrient components. The whole health of the motion system of the old is promoted and realized cooperatively through the functional effects of all nutrients and the progressive and scientific proportion of the nutrients, so that the daily activity and the life quality of the old are improved.
The composition provided by the invention can improve the functions of a human motion system from multiple aspects of promoting muscle growth, reducing muscle catabolism, improving osteoporosis, promoting articular cartilage repair and the like so as to improve the activity of old people. Meanwhile, the accumulation of free radicals in the body can be effectively eliminated, the effect of oxidative stress reaction in the body is reduced, and the body is healthier.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or instruments used are conventional products available from regular distributors, not indicated by the manufacturer.
Example 1
A nutritional composition for improving the function of the locomotor system of the elderly comprises, by weight, 15g of whey protein, 0.7g of whey protein peptide, 0.7g of wheat protein peptide, 10g of collagen peptide, 0.2g of casein phosphopeptide, 4g of leucine, β -hydroxy- β -methylbutyric acid, 0.5g of calcium, 0.2g of magnesium, 10g of chicken breast cartilage powder, 0.3g of chitosan oligosaccharide, 1.5g of dimethyl sulfone, 0.5g of curcumin, 42mg of vitamin B group, 8 μ g of vitamin D, 100mg of vitamin C, 14mg of vitamin E, and K290μg。
The nutritional composition of the present embodiment is more beneficial for improving muscle attenuation and promoting muscle growth.
Example 2
A nutritional composition for improving the function of the locomotor system of the elderly comprises, by weight, 10g of whey protein, 0.5g of whey protein peptide, 0.5g of wheat protein peptide, 10g of collagen peptide, 0.8g of casein phosphopeptide, 2g of leucine, β -hydroxy- β -methylbutyric acid, 0.7g of calcium, 0.3g of magnesium, 10g of chicken breast cartilage powder, 0.3g of chitosan oligosaccharide, 1.5g of dimethyl sulfone, 0.5g of curcumin, 42mg of vitamin B group, 8 μ g of vitamin D, 100mg of vitamin C, 14mg of vitamin E, and K290μg。
The nutritional composition is more beneficial to increasing bone density and improving osteoporosis.
Example 3
A nutritional composition for improving the function of the locomotor system of the elderly comprises, by weight, whey protein 10g, whey protein peptide 0.5g, wheat protein peptide 0.5g, collagen peptide 10g, casein phosphopeptide 0.2g, leucine 2g, β -hydroxy- β -methylbutyric acid 1g, calcium 0.5g, magnesium 0.2g, chicken breast cartilage powder 20g, chitooligosaccharideSugar 0.5g, dimethyl sulfone 2g, curcumin 0.8g, vitamin B42 mg, vitamin D8 μ g, vitamin C100mg, vitamin E14mg, vitamin K290μg。
The nutritional composition is more beneficial to promoting the growth of chondrocytes, accelerating the synthesis of bone matrix so as to promote the repair of articular cartilage, slow the degeneration of articular cartilage and improve the injury of articular cartilage.
Example 4
A capsule for improving motor system function of the elderly is prepared by: 1000g of the nutritional composition for improving the motor system function of the elderly in example 1 was taken and prepared into capsules of 0.5g per granule.
Example 5
A chewable tablet for improving motor system function of the elderly is prepared by the following steps: 1000g of the composition for improving the motor system function of the elderly in example 2 was mixed with 0.6% -1.0% by weight of magnesium stearate, and then compressed into 0.5g chewable tablets by a tablet press.
Example 6
A granule for improving motor system function of the elderly is prepared by: 1000g of the composition for improving the motor system function of the elderly in example 3 was taken, sieved and mixed, and then a proper amount of water was added to prepare a soft mass, which was granulated by a one-step granulator, and then dried, sorted, sieved, and canned into bags, each bag containing 15g of the composition.
Comparative example 1
A nutritional composition differing from example 1 only in that no whey protein is included.
Comparative example 2
A nutritional composition differing from example 2 only in that vitamin k2, vitamin D, were not included.
Comparative example 3
A nutritional composition differing from example 3 only in that it does not comprise chicken breast cartilage powder.
Comparative example 4
A nutritional composition differing from example 1 only in that whey protein was replaced with an equal amount of soy protein isolate.
Comparative example 5
The compound protein composition consists of 15g of whey protein, 0.7g of whey protein peptide, 0.7g of wheat protein peptide, 10g of collagen peptide and 0.2g of casein phosphopeptide.
Experimental example 1 experiment for improving muscle attenuation effect of exercise system
1. Experimental sample
The nutritional composition for improving the motor system function of the elderly prepared in example 1, the nutritional compositions prepared in comparative example 1 and comparative example 4, and the compound protein composition of comparative example 5, whey protein (the same as whey protein in example 1).
2. Experimental methods
84C 57BL/6 mice, 6-7 months old, were randomly divided into 7 groups of 12 mice each. Wherein 1 group is designated as a normal group, and 6 groups of mice are subcutaneously administered with dexamethasone at a concentration of 0.1ml/10g for 42 days to establish a muscle decay model. Corresponding treatments were given for 60 days thereafter. Before molding and before and after treatment, body composition (from Congjia biological products (China) Co., Ltd.) was measured for each group of mice by an Echo MRITM small body composition analyzer, and the muscle content was measured. The treatment of each group of mice was as follows:
normal group: 12, normal feed and water feeding only;
model group: 12, normal feed and water feeding only;
example 1 group: 12 individuals, gavage daily for 60 days except for normal feed and water feed, the nutritional composition of example 1 at 7.8 mg/g;
comparative example 1 group: 12, gavage 5.3mg/g of the nutritional composition of comparative example 1 every day for 60 consecutive days except for feeding with normal feed and water;
comparative example 4 group: 12, gavage daily except for normal feed and water feeding, and gavage daily for 60 days with 5.3mg/g of the comparative example 4 nutritional composition;
comparative example 5 group: 12, except for feeding with normal feed and water, the stomach is drenched every day, and the compound protein composition of comparative example 5 is 4.5 mg/g for 60 days continuously;
whey protein group: 12 animals except for normal feed and water, were gavaged daily for 60 days with 2.5mg/g whey protein.
Note: the molding principle is as follows: glucocorticoids promote protein breakdown in a variety of tissues, such as muscle, skin, lymphatic, and bone tissues. At the same time, it can inhibit protein synthesis and reduce assimilation, so that negative nitrogen balance appears, muscles and lymph tissue are atrophied, and wound healing is slow. Clinical studies have demonstrated that patients treated with glucocorticoids have a significant reduction in muscle content. Dexamethasone is a hormone medicine with the highest potency and the longest action duration in glucocorticoid, so that the establishment of a muscle decay syndrome model by utilizing dexamethasone has the advantages of short period, obvious effect and the like. Dexamethasone induces muscle decline in mice primarily by promoting protein degradation.
3. Results of the experiment
See table 1 below.
TABLE 1 muscle content (g) of mice in each group
Group of Before molding Before post-processing of molding After treatment (gavage for 60 days)
Normal group 23.04±1.56 23.30±1.35 24.26±1.66
Model set 23.27±1.87 18.12±1.27* 19.44±1.59
EXAMPLE 1 group 23.25±1.23 18.98±1.13* 24.05±1.55##
Comparative example 1 group 23.86±1.35 19.21±1.73* 22.09±1.18#
Comparative example 4 group 23.47±1.32 19.13±1.27* 22.79±1.42#
Comparative example 5 group 23.41±1.78 19.55±1.38* 22.32±1.36#
Whey protein group 23.20±1.40 19.34±1.31* 21.33±1.28#
Note:*indicates that P < 0.05 compared to the normal group;**indicates that P < 0.01, compared to the normal group.
#Represents that P is less than 0.05 compared with the model control group;##indicating that P < 0.01 compared to model control.
As can be seen from Table 1, the muscle content of the normal group mice is significantly higher than that of the model group and other groups before the post-molding treatment (P < 0.05); the model is successfully established; compared with the model group, the muscle content of the group of example 1 is very different (P < 0.01); the muscle content of the group of example 1 is also improved remarkably (P < 0.05) compared with the group of comparative example 1, the group of comparative example 4, the group of comparative example 5 and the group of whey protein; the muscle content of the mice in the groups of the comparative example 1 and the comparative example 4 is better than that of the mice in the groups of the comparative example 5 and the whey protein group, but the difference is not significant (P is more than 0.05).
The experimental results show that in the aspect of improving the muscle attenuation function of the motor system of the old, the single component (such as whey protein, whey protein peptide and wheat protein peptide) has a synergistic effect, and the treatment effect of the composition is obviously better than that of one or more components used independently.
Experimental example 2 osteoporosis effect experiment for improving exercise system
1. Experimental sample
Nutritional composition for improving motor system function of elderly prepared in example 2, nutritional composition prepared in comparative example 2, calcium + VD composition (consisting of 0.7g calcium, vitamin D8 μ g).
2. Experimental methods
60 SD females are infertile with 6 months of age, and are randomly divided into 5 groups of 12 animals each. Wherein 1 group was designated as normal group, and the other 4 groups of rats were subjected to bilateral ovariectomy for osteoporosis modeling. Corresponding treatments were given on day 5 post-surgery for 60 days. After treatment, each group of rats was examined for mid-femoral bone density using an X-RAY analyzer (caretresam FXPRO). The treatment of each group of rats was as follows:
normal group: 12, only fed with no soybean and its product feed and water;
model group: 12, only fed with no soybean and its product feed and water;
example 2 group: 12 animals except for feeding with no soybean and its product feed and water, gavage the stomach every day with 3.2mg/g of the nutritional composition of example 2 for 60 consecutive days;
comparative example 2 group: 12, except feeding the soybean, the feed prepared from the soybean and the product thereof and water, the gastric lavage of the comparative example 2 is performed every day, and the nutrient composition is 3.2mg/g and is continuously used for 60 days;
calcium + VD group: 12 animals except for soybean and its product feed and water, were fed by intragastric administration of 58. mu.g/g of calcium + VD composition (consisting of 0.7g of calcium and 8. mu.g of vitamin D) for 60 consecutive days.
Note: the molding principle is as follows: at present, the domestic and foreign researches mostly use classical operation to cut off bilateral ovary models, the model well simulates the characteristics of osteoclast activity acceleration caused by the decrease of human estrogen, high-conversion bone metabolism for compensatory enhancement of osteoblast function and the like, and the model is a common animal model for simulating osteoporosis at present.
3. Results of the experiment
See table 2 below.
TABLE 2 bone Density measurement results (g.m) for rats of each group3)
Group of Bone mineral density content
Normal group 7.40±0.53
Model set 5.01±0.29*
EXAMPLE 2 group 6.55±0.16##
Comparative example 2 group 5.91±0.12#
Calcium + VD group 5.83±0.17#
Note:*indicates that P < 0.05 compared to the normal group;**indicates that P < 0.01, compared to the normal group.
#Represents that P is less than 0.05 compared with the model control group;##indicating that P < 0.01 compared to model control.
As can be seen from Table 2, the bone density in the normal group is significantly higher than that in the model group (P < 0.05); the model is successfully established; compared with the model group, the bone density of the group of example 2 is very different (P < 0.01); the bone density of the group of example 2 is also improved significantly (P < 0.05) compared with the group of comparative example 2 and the calcium + VD group; the rats in the comparative example 2 have better bone density improvement than the calcium + VD group, but the difference is not significant (P is more than 0.05).
The experimental results show that the treatment effect of the group in example 2 is significantly better than that of a few of the components which are used independently in the aspect of improving the osteoporosis function of the motor system of the elderly.
Experimental example 3 experiment for improving gonarthritis effect of locomotor system
1. Experimental sample
Nutritional composition for improving motor system function of elderly prepared in example 3, nutritional composition prepared in comparative example 3, glucosamine + chondroitin sulfate composition (consisting of glucosamine 0.5g, chondroitin sulfate 0.2 g).
2. Experimental methods
60 SD rats, randomly divided into 5 groups of 12 rats each. In the other 4 groups, iodoacetic acid (1mg, 50. mu.l) was injected into the knee joint cavity of the right knee joint of rats 1 time per week for 4 consecutive times to perform knee arthritis modeling. Rats in each group were given a corresponding treatment one week before the start of molding. 30 days after the model building is finished, the rats are sacrificed to extract the cartilage tissue specimens of the right knee joint, and the expression of type II collagen and cartilage proteoglycan (aggrecan) in the cartilage of the right knee joint of each group of rats is detected by a reverse transcription-polymerase chain reaction (RT-PCR) method. The treatment of each group of rats was as follows:
normal group: 12 animals fed with normal feed and water only
Model group: 12 animals fed with normal feed and water only
Example 3 group: 12 animals except for soybean and its product feed and water, gavage the stomach every day with 8mg/g of the nutritional composition of example 3 for 65 consecutive days
Comparative example 3 group: 12 animals except for feeding soybean and its product feed and water, and gavage the stomach every day to obtain the nutritional composition of comparative example 3 (4.7 mg/g) for 65 days
Glucosamine + chondroitin sulfate group: 12 animals except semen glycines and its product feed and water, respectively, feeding with 250 μ g/g composition (composed of glucosamine 0.5g and chondroitin sulfate 0.2 g) of glucosamine and chondroitin sulfate for 65 days
Note: the principle of osteoarthritis molding is as follows: the iodoacetic acid is selected for injecting in the knee joint cavity, so that the original steady state of the joint cavity is changed, MIA has certain destructive effect on articular cartilage and peripheral synovial membrane toughness, and the metabolism of cartilage and subchondral bone is changed, the stability of the internal environment of the joint is destroyed, cartilage cells are apoptotic, and cartilage is abraded. Meanwhile, other structures in the joint are damaged, and fibrous tissues around the joint are proliferated to form osteophytes, which finally develop into osteoarthritis.
Collagen type ii and cartilage proteoglycan are important components of articular cartilage and also important marker components of articular cartilage degeneration.
3. Results of the experiment
The results of the specific experiments are shown in Table 3 below.
TABLE 3 measurement results of osteoarticular index of rats in each group
Group of Expression of type II collagen (%) Expression of cartilage proteoglycan (%)
Normal group 100.0 100.0
Model set 50.3±2.2** 68.5±3.4**
EXAMPLE 3 group 84.5±3.1## 92.3±4.7##
Comparative example 3 group 73.0±5.4## 78.2±6.1##
Glucosamine + chondroitin sulfate group 75.6±4.5## 79.8±4.7##
Note:*indicates that P < 0.05 compared to the normal group;**indicates that P < 0.01, compared to the normal group.
#Represents that P is less than 0.05 compared with the model control group;##indicating that P < 0.01 compared to model control.
As can be seen from Table 3, the expression of collagen type II and cartilage proteoglycan in the normal group was significantly higher than that in the model group (P < 0.01); the model is successfully established;
the increase in type II collagen and cartilage proteoglycan was very significantly different in the example 3 group compared to the model group (P < 0.01);
the group of example 3 also showed a very significant improvement (P < 0.05) in the case of type II collagen and cartilage proteoglycan compared to the group of comparative example 3, glucosamine + chondroitin sulfate;
the expression of type II collagen and cartilage proteoglycan of the glucosamine and chondroitin sulfate group rats is better than that of the comparative example 3, but the difference is not significant (P is more than 0.05).
The experimental results show that the treatment effect of the group in example 3 is significantly better than that of a few of the components which are used independently in the aspect of improving the functions of the bone joints of the motion system of the old.
EXAMPLE 4 product stability (high temperature, high humidity acceleration)
1. Test sample
The nutritional composition for improving the motor system function of the elderly in example 1 is subpackaged into 45g of packaging bags according to a conventional method.
2. Experimental methods
The shelf life of the product is estimated to be at least 12 months by referring to the like products. The shelf life at different temperatures is initially assumed to be as shown in table 4 below, with a 1-fold increase in reaction for each 10 ℃ increase in temperature.
TABLE 4 accelerated test temperature and shelf life corresponding table
Temperature (. degree.C.) Shelf life estimation (moon)
20 12
30 6
40 3
50 1.5
60 0.75(23 days)
The test samples are placed at the temperature of 60 ℃ and the humidity of 75% to carry out high-temperature high-humidity accelerated test, and the detection of relevant indexes is carried out on the 0 th day and the 23 rd day. The method mainly aims to preliminarily predict the shelf life of the product and the stability, physical stability, water activity and sensory state of each nutrient component in the shelf life range.
The detection of the nutrient components comprises main nutrient components of protein, fat and carbohydrate, and easily lost nutrient components of vitamin B group, vitamin C and vitamin E.
And (3) detecting physical stability: the product is brewed according to a certain proportion and then is detected by a LUMiSizer 611 type rapid stability analyzer to detect the Slope value (the Slope value represents the change speed of the light transmittance of the liquid in a period of time, the curve Slope value can be obtained by drawing the whole light transmittance versus time, the larger the value is, the faster the light transmittance of the liquid is changed, the worse the liquid stability is, otherwise, the smaller the Slope value is, the more stable the liquid is).
And (3) water activity detection: the ease of growth and reproduction of the microorganism can be evaluated. Each microorganism has its minimum water activity requirement for growth and reproduction in food. If the water activity of the food product is below this requirement, the growth and propagation of microorganisms is inhibited. At water activities below 0.6, most microorganisms are unable to grow.
The sensory state evaluation includes: color, smell, tissue state, color, smell, solubility, etc.
3. Results of the experiment
Table 5 stability results of nutritional ingredients
Nutrient composition Day 0 Day 23
Protein g/100g 61.5 60.2
Fat g/100g 2.5 2.7
Carbohydrate g/100g 16.5 17.2
Water content% 2.55 2.78
Vitamin B1mg/100g 25.0 27
Vitamin B2mg/100g 26.2 28.1
Vitamin B6mg/100g 25.8 26.5
Vitamin C mg/100g 202 195
Vitamin E mg/100g 27.0 25.8
TABLE 6 physical stability and sensory status
From the above results, the shelf life of the product is more than 12 months. Within the shelf life, the product has stability characteristics in terms of nutrient content, physical stability and sensory state, and can meet the quality requirements of the product.
Experimental example 5 trial feeding experiment for population
1. Test sample
The nutritional composition for improving the motor system function of the elderly in example 1 is subpackaged into 45g of packaging bags according to a conventional method.
2. Experimental methods
The number of crowds: 50 persons;
eating time/amount: 60 days, 1 bag (45g) per day;
population inclusion criteria: is more than or equal to 60 years old, is not limited by men and women, and has one of health problems of osteoporosis, knee joint cartilage degeneration and muscle attenuation.
Osteoporosis determination criteria: detecting the calcaneus bone density by an ultrasonic bone densitometer, and diagnosing the calcaneus bone density as osteoporosis;
knee joint cartilage degradation judgment standard: detecting the knee joints by X-ray, wherein one leg is diagnosed as the cartilage degeneration of the knee joint;
muscle attenuation determination criteria: the following three conditions are simultaneously satisfied:
① grip strength is reduced by < 26kg for men and < 18kg for women, ② pace speed is reduced by < 0.8m/s, ③ skeletal muscle mass is reduced by < 7.0kg/m for men2Female < 5.8kg/m2。
Before the beginning of the test diet, the subjects were tested for muscle content and bone mass by a body composition tester. After completion of the feeding trial, the subjects filled out a questionnaire while again performing the measurement of muscle content and bone mass.
The option of having 5 or more questions in the questionnaire as "get good" is valid. The specific questionnaire contents are as follows in table 7:
TABLE 7 trial questionnaire for the population
Increases in muscle content and bone mass, values above 10% are effective.
3. Results of the experiment
TABLE 8 statistics of test results
Questionnaire survey/n Increased muscle content Increase in bone mass
Number of effective persons 41 35 38
Number of invalid persons 9 15 12
High efficiency 82％ 70％ 76％
The data show that the effective rate of the formula disclosed in example 1 after being eaten for 60 days is more than 70%, and the formula has a remarkable improvement effect on the problems of the sports systems such as osteoporosis, knee joint cartilage degeneration and muscle attenuation of the old.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (9)

1. A nutritional composition for improving the motor system function of the elderly is characterized by comprising the following components in parts by weight: 10-15 parts of whey protein, 0.5-1 part of whey protein peptide, 0.5-1 part of wheat protein peptide, 2-10 parts of collagen peptide, 0.05-0.15 part of casein phosphopeptide, 2-5 parts of leucine, 0.5-3 parts of beta-hydroxy-beta-methylbutyric acid, 0.5-1 part of calcium, 0.2-0.5 part of magnesium, 5-20 parts of chicken breast cartilage powder, 0.1-0.5 part of chitosan oligosaccharide, 0.5-2 parts of dimethyl sulfone, 0.1-1 part of curcumin and 0.8-1.2 parts of vitamin mixture.
2. The nutritional composition for improving the motor system function of the elderly as claimed in claim 1, which comprises the following components in parts by weight: 12-15 parts of whey protein, 0.5-0.8 part of whey protein peptide, 0.5-0.8 part of wheat protein peptide, 3-10 parts of collagen peptide, 0.05-0.1 part of casein phosphopeptide, 2-4 parts of leucine, 1-3 parts of beta-hydroxy-beta-methylbutyric acid, 0.5-0.8 part of calcium, 0.2-0.4 part of magnesium, 10-20 parts of chicken breast cartilage powder, 0.2-0.5 part of chitosan oligosaccharide, 1-2 parts of dimethyl sulfone, 0.5-1 part of curcumin and 0.9-1.1 part of vitamin mixture;
preferably, the composition consists of the following components in parts by weight: 14-15 parts of whey protein, 0.6-0.7 part of whey protein peptide, 0.6-0.7 part of wheat protein peptide, 5-10 parts of collagen peptide, 0.05-0.8 part of casein phosphopeptide, 3-4 parts of leucine, 2-3 parts of beta-hydroxy-beta-methylbutyric acid, 0.5-0.6 part of calcium, 0.2-0.3 part of magnesium, 15-20 parts of chicken breast cartilage powder, 0.3-0.5 part of chitosan oligosaccharide, 1.5-2 parts of dimethyl sulfone, 0.5-0.8 part of curcumin and 0.9-1.0 part of vitamin mixture.
3. Nutritional composition for improving the motor system function of the elderly according to claim 1 or 2, wherein the vitamin mixture comprises vitamin B group, vitamin D, vitamin C, vitamin E, vitamin K2。
4. Nutritional composition for improving the motor system function of elderly according to any of claims 1-3,
the content of each vitamin in each 1g of the vitamin mixture is as follows: vitamin B group 12-42mg, vitamin D3-10 μ g, vitamin C30-100 mg, vitamin E5-15 mg, vitamin K270-90μg；
Preferably, the content of each vitamin in each 1g of the vitamin mixture is: vitamin B20-42 mg, vitamin D5-10 μ g, vitamin C50-100mg, vitamin E10-15 mg, and vitamin K280-90μg；
Further preferably, the content of each vitamin in each 1g of the vitamin mixture is: vitamin B42 mg, vitaminVitamin D8 μ g, vitamin C100mg, vitamin E14mg, and vitamin K290μg。
5. The nutritional composition for improving the motor system function of the elderly as claimed in claim 1, which comprises whey protein 15g, whey protein peptide 0.7g, wheat protein peptide 0.7g, collagen peptide 10g, casein phosphopeptide 0.2g, leucine 4g, β -hydroxy- β -methylbutyrate 3g, calcium 0.5g, magnesium 0.2g, chicken breast cartilage powder 10g, chitosan oligosaccharide 0.3g, dimethyl sulfone 1.5g, curcumin 0.5g, vitamin B42 mg, vitamin D8 μ g, vitamin C100mg, vitamin E14mg, vitamin K290 mu g of the mixture; or,
comprises the following components by weight portion of 10g of whey protein, 0.5g of whey protein peptide, 0.5g of wheat protein peptide, 10g of collagen peptide, 0.8g of casein phosphopeptide, 2g of leucine, 1g of β -hydroxy- β -methylbutyric acid, 0.7g of calcium, 0.3g of magnesium, 10g of chicken breast cartilage powder, 0.3g of chitosan oligosaccharide, 1.5g of dimethyl sulfone, 0.5g of curcumin, 42mg of vitamin B group, 8 mu g of vitamin D, 100mg of vitamin C, 14mg of vitamin E, and K of vitamin K290 mu g of the mixture; or,
comprises the following components by weight portion, 10g of whey protein, 0.5g of whey protein peptide, 0.5g of wheat protein peptide, 10g of collagen peptide, 0.2g of casein phosphopeptide, 2g of leucine, 1g of β -hydroxy- β -methylbutyric acid, 0.5g of calcium, 0.2g of magnesium, 20g of chicken breast cartilage powder, 0.5g of chitosan oligosaccharide, 2g of dimethyl sulfone, 0.8g of curcumin, 42mg of vitamin B group, 8 mu g of vitamin D, 100mg of vitamin C, 14mg of vitamin E, and K290μg。
6. A process for preparing a nutritional composition for improving the motor system function of the elderly as claimed in any of claims 1 to 5, which comprises mixing the raw materials in proportion.
7. A formulation comprising the nutritional composition for improving motor system function in elderly as claimed in any of claims 1-5; furthermore, the preparation also contains auxiliary materials and/or additives used in the fields of food and health-care food; alternatively, the formulation further comprises a pharmaceutically acceptable carrier.
8. The formulation according to claim 7, characterized in that it is a tablet, capsule, granule, powder or tabletted candy.
9. Use of a nutritional composition according to any one of claims 1-5 or a formulation according to claim 7 or 8 for the preparation of a food or health product or a pharmaceutical product for improving the motor system function in elderly people.
CN201710693890.2A 2017-08-14 2017-08-14 A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof Pending CN107348522A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710693890.2A CN107348522A (en) 2017-08-14 2017-08-14 A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710693890.2A CN107348522A (en) 2017-08-14 2017-08-14 A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof

Publications (1)

Publication Number Publication Date
CN107348522A true CN107348522A (en) 2017-11-17

Family

ID=60286742

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710693890.2A Pending CN107348522A (en) 2017-08-14 2017-08-14 A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107348522A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108157878A (en) * 2018-01-09 2018-06-15 纽斯葆广赛（广东）生物科技股份有限公司 A kind of high fine calcium fortification collagen jelly and preparation method thereof
WO2019101700A1 (en) * 2017-11-21 2019-05-31 Nestec S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
CN110214947A (en) * 2019-06-12 2019-09-10 宁波依萃健生物科技有限公司 A kind of prevention and treatment osteoarthritis composition
CN112401240A (en) * 2020-12-10 2021-02-26 泓博元生命科技（深圳）有限公司 Mitochondrial sports nutritional compositions
CN115918914A (en) * 2022-12-01 2023-04-07 宝健（北京）生物技术有限公司 Oral nutritional supplement containing compound protein, preparation and application

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248882A (en) * 2008-03-28 2008-08-27 北京东方兴企食品工业技术有限公司 Nutrition food product with promoting health of bones and bone arthrosis
CN102133395A (en) * 2011-03-18 2011-07-27 上海海维生物科技有限公司 Skeleton health-care product or medicinal composite and application thereof
CN103079415A (en) * 2010-07-07 2013-05-01 N.V.努特里西阿公司 Nutritional composition for the stimulation of muscle protein synthesis
CN105363023A (en) * 2015-11-11 2016-03-02 深圳太太药业有限公司 Composition with effects of protecting joints and increasing bone mineral density and preparation method of composition
CN105520135A (en) * 2015-12-20 2016-04-27 雷西云 Healthy food with function of treating osteoporosis
CN105725190A (en) * 2016-02-15 2016-07-06 北京东方兴企食品工业技术有限公司 Functional nutrient food for improving joints
CN106072573A (en) * 2016-07-05 2016-11-09 郑州和正生物科技有限公司 A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible
CN106213492A (en) * 2016-07-22 2016-12-14 山东博奥克生物科技有限公司 A kind of lifter motion function also increases health-oriented products and the preparation method of bone density

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248882A (en) * 2008-03-28 2008-08-27 北京东方兴企食品工业技术有限公司 Nutrition food product with promoting health of bones and bone arthrosis
CN103079415A (en) * 2010-07-07 2013-05-01 N.V.努特里西阿公司 Nutritional composition for the stimulation of muscle protein synthesis
CN102133395A (en) * 2011-03-18 2011-07-27 上海海维生物科技有限公司 Skeleton health-care product or medicinal composite and application thereof
CN105363023A (en) * 2015-11-11 2016-03-02 深圳太太药业有限公司 Composition with effects of protecting joints and increasing bone mineral density and preparation method of composition
CN105520135A (en) * 2015-12-20 2016-04-27 雷西云 Healthy food with function of treating osteoporosis
CN105725190A (en) * 2016-02-15 2016-07-06 北京东方兴企食品工业技术有限公司 Functional nutrient food for improving joints
CN106072573A (en) * 2016-07-05 2016-11-09 郑州和正生物科技有限公司 A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible
CN106213492A (en) * 2016-07-22 2016-12-14 山东博奥克生物科技有限公司 A kind of lifter motion function also increases health-oriented products and the preparation method of bone density

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019101700A1 (en) * 2017-11-21 2019-05-31 Nestec S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
CN111315239A (en) * 2017-11-21 2020-06-19 雀巢产品有限公司 Compositions and methods for using oleuropein or curcumin for muscle mass and/or muscle mass
CN108157878A (en) * 2018-01-09 2018-06-15 纽斯葆广赛（广东）生物科技股份有限公司 A kind of high fine calcium fortification collagen jelly and preparation method thereof
CN110214947A (en) * 2019-06-12 2019-09-10 宁波依萃健生物科技有限公司 A kind of prevention and treatment osteoarthritis composition
CN112401240A (en) * 2020-12-10 2021-02-26 泓博元生命科技（深圳）有限公司 Mitochondrial sports nutritional compositions
CN115918914A (en) * 2022-12-01 2023-04-07 宝健（北京）生物技术有限公司 Oral nutritional supplement containing compound protein, preparation and application

Similar Documents

Publication Publication Date Title
CN107348522A (en) A kind of alimentation composition for improving the elderly&#39;s kinematic system function and preparation method thereof
CN101248882B (en) Nutrition food product with promoting health of bones and bone arthrosis
US8703174B2 (en) Joint preserving nutritional vitamin, mineral and herbal pet supplement
DK2730286T3 (en) Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints
CN103783532B (en) A kind of composite protein powder of anti-sarcopenia decay and preparation method thereof
CN106235311A (en) A kind of compositions promoting skeletal system health and application thereof
CN111972672A (en) Composition with muscle increasing function and application thereof
TWI830696B (en) Compositions for inhibiting muscle fiber degeneration
CN105451578A (en) Chromatographic separation of sugars using blend of cation exchange resins
CN111467481A (en) Composition for improving and/or preventing osteoarthritis and application thereof
CN111569052A (en) Composition for increasing bone mineral density of climacteric women and health product and application thereof
ZA200606419B (en) Glycine and/or proline for use in cartilage affecting conditions
CN101690591A (en) Yak marrow polypeptide bone growing and height increasing tablets (powder)
JPH09124473A (en) Enhancer for physical fitness
AU2021101026A4 (en) A nutritional composition for improving the motor system function of the elderly and its preparation method and application
CN103238839A (en) Food composition containing collagen used for maintaining joints
CN104223120A (en) Food formula containing low-molecule chondroitin sulfate for special diet for patients suffering from meniscus injury
CN108719998A (en) An oral dietary supplement for the treatment of osteoarthritis
JP2005232089A (en) Orally administrable functional agent having bone quantity-increasing activity
CN106036387A (en) Super chenopodium quinoa willd nutritional packet for promoting growth of children
CN104888192A (en) Sea cucumber glucosamine preparation for increasing bone mineral density, and production method thereof
CN111012900B (en) Composition with bone mineral density increasing function and preparation method and application thereof
AU2018252158B2 (en) A composition with mobility benefits in ageing, healthy subjects
US20230398104A1 (en) Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for rehabilitation
CN101999662A (en) Capsule for treating osteoporosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Yang Yuexin

Inventor after: He Mei

Inventor after: Chen Chaoqing

Inventor after: Wang Xuemin

Inventor after: Zhang Yan

Inventor after: Wu Minhui

Inventor after: Han Lili

Inventor before: Chen Chaoqing

Inventor before: He Mei

Inventor before: Wang Xuemin

Inventor before: Zhang Yan

Inventor before: Wu Minhui

Inventor before: Han Lili

CB03 Change of inventor or designer information